Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19277458 | 0.97 | POLB (0.61) | POLBSMN1; SMN2ALDH1A1HTTHSD17B10 | |
| SCHEMBL20346316 | 0.81 | SMN1; SMN2 (0.97) | POLBSMN1; SMN2ALDH1A1HTTHSD17B10 | |
| SCHEMBL12425968 | 0.79 | SMN1; SMN2 (1.00) | POLBSMN1; SMN2ALDH1A1HTTHSD17B10 | |
| SCHEMBL17048441 | 0.75 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1HTTHSD17B10TSHR | |
| SCHEMBL19277047 | 0.74 | SLC6A3 (0.49) | L3MBTL1 | |
| SCHEMBL1002282 | 0.74 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1HTTHSD17B10TSHR | |
| SCHEMBL20590845 | 0.72 | SMN1; SMN2 (0.53) | POLBSMN1; SMN2ALDH1A1HTTHSD17B10 | |
| SCHEMBL19277486 | 0.72 | PSIP1 (0.52) | ALDH1A1GAANPC1RAB9A | |
| SCHEMBL31192532 | 0.72 | PSIP1 (0.52) | ALDH1A1GAANPC1RAB9A | |
| SCHEMBL10586812 | 0.71 | TSHR (0.53) | SMN1; SMN2ALDH1A1HSD17B10TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| WO-2017141927-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | 大正製薬株式会社 | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | POLB 4110/4885SMN1; SMN2 4769/4885ALDH1A1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.